Estados Unidos - inglês - NLM (National Library of Medicine)

lek pharmaceuticals - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - tablet - 2.5 mg - bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. bromocriptine mesylate treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. in cases where adenectomy is elected, a course of bromocriptine mesylate therapy may be used to reduce the tumor mass prior to surgery. acromegaly bromocriptine mesylate tablets are indicated in the treatment of acromegaly. bromocriptine mesylate therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately one-half of patients treated, although not usually to normal levels. since the effects of external pituitary radiation may not become maximal for

Canadá - inglês - Health Canada

pro doc limitee - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Canadá - inglês - Health Canada

pharmel inc - bromocriptine (bromocriptine mesylate) - tablet - 2.5mg - bromocriptine (bromocriptine mesylate) 2.5mg - ergot-derivative dopamine receptor agonists

Canadá - inglês - Health Canada

pharmel inc - bromocriptine (bromocriptine mesylate) - capsule - 5mg - bromocriptine (bromocriptine mesylate) 5mg - ergot-derivative dopamine receptor agonists

Estados Unidos - inglês - NLM (National Library of Medicine)

avera mckennan hospital - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 5 mg

Estados Unidos - inglês - NLM (National Library of Medicine)

kaiser foundation hospitals - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - bromocriptine 2.5 mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

focus pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) - tablet - 2.5 mg - active: bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: · bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - bromocriptine mesilate - oral tablet - 2.5mg